Former Finance Minister Arun Jaitley Dies At 66
Arun Jaitley, the former finance minister and one of Prime Minister Narendra Modi's closest associates, died in hospital on Saturday, nearly two weeks after he was admitted following breathing difficulties, officials said.
Mr Jaitley, 66, a senior leader of the Bharatiya Janata Party (BJP), stepped down as finance minister in January due to ill health, just months before elections.
"With the demise of Arun Jaitley Ji, I have lost a valued friend, whom I have had the honour of knowing for decades," PM Modi said on Twitter. "His insight on issues and nuanced understanding of matters had very few parallels."
Mr Jaitley was admitted to All India Institute Medical Sciences in New Delhi on August 9.
A diabetic, his health had worsened after he underwent a kidney transplant in May last year. He also had to skip the presentation of the interim budget in February when he was in hospital in the United States for cancer treatment.
The lawyer-turned-politician also had triple heart bypass surgery when he was 52.
The BJP lost another veteran party leader and former minister of external affairs when Sushma Swaraj died after a cardiac arrest earlier this month.
During his tenure as finance minister, Jaitley led the enactment of a bankruptcy code and a national goods and services tax law that had languished for almost 20 years.
The implementation of the GST resulted in job losses for thousands of workers in small businesses, adding to his mixed record on economic management.
The Indian economy has been under a cloud for months, with latest government estimates showing it had slowed to a five-year low of 5.8 per cent in January-March as a result of sluggish domestic and global demand and little growth in private investment.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.